PACTR201701001921166Other未知
Age de-escalation study to assess safety and immunogenicity of recombinant E. coli BK-SE36 malaria vaccine candidate formulated with CpG adjuvant administered intramuscularly in healthy malaria exposed African adults and children living in Burkina Faso.
obelpharma Co., Ltd0 个研究点目标入组 135 人开始时间: 2016年12月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •Specific inclusion criteria for cohort 1 (adults 21-45 years old)
- •¿Female or male subjects aged 21 to 45 years inclusive at the time of the first vaccination
- •¿Residing within the Ouagadougou health region and planning to stay for the study duration
- •¿General good health based on medical history and clinical examination
- •¿Written informed consent obtained before any trial procedure
- •¿Female and male volunteers practicing /willing to practice contraceptive methods recommended by the national health system for at least four (4) weeks before the first vaccination (for female participants only) and up to four (4) weeks after the third vaccination.
- •Specific inclusion criteria for cohort 2 (children 5-10 years old)
- •¿Female or male subjects aged 5 to 10 years inclusive at the time of first vaccination.
- •Specific inclusion criteria for cohort 3 (children 12-24 months)
- •¿Female or male subjects aged 12 to 24 months inclusive at the time of first vaccination.
- •Common inclusion criteria for cohorts 2 and 3
- •¿Residing within the Ouagadougou health region and planning to stay for the study duration
- •¿Appear to be in generally good health based on malnutrition index and clinical and laboratory investigations
- •¿Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child. Where parent(s)/guardian(s) are not literate, the consent form will be countersigned by an impartial witness
- •¿Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits) will be enrolled in the study. The trial period for each subject is 14 months (12 months + 8 weeks screening).
排除标准
- •Specific non-inclusion criteria for cohort 1
- •¿ Positive pregnancy test
- •¿ Currently breastfeeding
- •¿ Suspected or current known alcohol or drug abuse
- •Specific non-inclusion criteria for cohort 3
- •¿Weight-for-age Z score of less than ¿3 or other relevant clinical signs of malnutrition
- •For cohort 1, 2 and 3
- •¿Previous participation in any malaria vaccine trial
- •¿History of blood transfusion within the last 3 months
- •¿Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers
- •¿Any clinically significant laboratory abnormalities on screened blood samples outside the normal range, as defined at the clinical trial site. Specifically:
- •oHaemoglobin less than 8.0 g/dL,
- •oSerum Creatinine concentration greater than 70 µmol/L,
- •oSerum ALT concentration greater than 45 U/L,
- •oLow platelet count (< 100,000/mm3)
- •¿Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior to recruitment. (For corticosteroids, this will mean prednisone, or equivalent, ¿ 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •¿Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination (No testing will be done for HIV)
- •¿A family history of congenital or hereditary immunodeficiency
- •¿History of auto immune disease
- •¿Major congenital defects
- •¿Subjects with splenectomy
- •¿History of anaphylaxis or known severe hypersensitivity to any of the vaccine components (adjuvant or antigen or excipient)
- •¿Administration of gamma globulin: 4 weeks prior to and after each vaccination; if administration is necessary during the study period, the volunteer will be withdrawn from the study
- •¿Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s)
- •¿Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period
- •¿Current participation in another clinical trial, or within 12 weeks of this study
- •¿Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.
研究者
相似试验
已完成
1 期
Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in TanzaniaMalaria,FalciparumNCT04318002University of Oxford60
已完成
1 期
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.MalariaNCT02859350Sanaria Inc.135
已完成
1 期
EMaBS TB Vaccine StudySafetyImmunogenicityNCT03681860University of Oxford72
终止
1 期
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.Malaria,FalciparumNCT04271306University of Oxford34
已完成
不适用
Dose-escalation study to evaluate safety and tolerability of cellobiose in healthy subjectsHealthy volunteersDRKS00012972Pfeifer & Langen GmbH & Co. KG48